Author Archives: admin


How safe is stem cell therapy for children affected with autism spectrum disorder – Video


How safe is stem cell therapy for children affected with autism spectrum disorder
In conversation with Dr Alok Sharma (MS, MCh.) Professor of Neurosurgery Head of Department, LTMG Hospital LTM Medical College, Sion, Mumbai. Explains, How safe is stem cell therapy for...

By: Neurogen Brain and Spine Institute

Originally posted here:
How safe is stem cell therapy for children affected with autism spectrum disorder - Video

Saved from amputation – how a stem cell gel rebuilt my shattered leg

Clive Randell, 57, injured his leg in a motorcycle accident in 2011 Thanks to a new stem cell procedure, he can now ride his bike again Stem cells taken from the pelvis are blended with gel to 'glue' the bone

By David Gerrie

Published: 16:01 EST, 12 July 2014 | Updated: 02:33 EST, 13 July 2014

A pioneering stem cell procedure to repair fractured bones could provide a lifeline for accident victims facing the amputation of a limb.

The development involves harvesting stem cells master cells that are able to transform into any kind of body tissue from the patients pelvis, blending them with a specially created gel and injecting the solution into the damaged bone.

One patient already benefiting is lifelong motorcycle enthusiast Clive Randell who suffered horrific injuries to his left leg when his Harley-Davidson was rammed by a car in 2011.

On yer bike: Clive Randell, 57, pictured with his 'saviour' Professor Anan Shetty at Kents Canterbury Christ Church University, can now ride his bike again after undergoing the new stem cell procedure

He suffered multiple open fractures, leaving bone protruding through the skin, and extensive skin loss. Doctors repeatedly told him his leg would have to be amputated.

Today, though, Clive, 57, is back on his feet and, astonishingly, also his bike thanks to the ground-breaking stem-cell treatment.

Follow this link:
Saved from amputation - how a stem cell gel rebuilt my shattered leg

California stem cell agency to review dealings with StemCells Inc.

Californias stem cell agency announced Wednesday it was taking steps to deal with a risk of conflict of interest two days after its former president took a position with a company that the state agency had been funding.

Newark, Calif.-based StemCells Inc. announced that Alan Trounson would be joining its board of directors a week after Trounson left the top spot at the California Institute for Regenerative Medicine, according to California Stem Cell Report, a blog that follows developments related to the state agency.

The movehas an appearance of a serious conflict of interest, said John M. Simpson, director of the stem cell project for Santa Monica-based nonprofit Consumer Watchdog, in an interview.

The thing smacks as if this is StemCells Inc. giving a payback to Trounson after the agency awarded $19 million to StemCells Inc. Thats just the way it looks, Simpson said. And I think they have to explain quite clearly why that is not the case.

In a statement, the state stem cell agency said it had not known of the move and learned of Trounson's new position from a press release.

We take even the appearance of conflicts of interest very seriously, the agencys current president, C. Randal Mills, said in a statement, adding that they would be taking actions to address mounting concerns. We understand that the appointment of CIRMs former president to the board of directors of a CIRM loan recipient creates a risk of a conflict of interest.

Under current law, it is illegal for Trounson to communicate with the stem cell agencys board members or employees on behalf of his company to further its interests. The restriction lasts one year; Simpson argued that such a restriction should last for two years.

The agency has also banned its employees and its governing board from communicating with Trounson about any matter regarding StemCells Inc., and will be reviewing all of its work relating to the company, which the state agency says is receiving funding for Alzheimers research.

Simpson praised the agencys actions, but pointed out that conflict of interest has been a recurrent issue between the state agency and the organizations it funds. The stem cell agency was created by Proposition 71 in 2004 to distribute $3 billion of taxpayer funds to companies and institutions performing stem cell research.

With some 90% of the agency's grants having gone to institutions with representatives on its board, Times columnist Michael Hiltzik wrote in a 2012 story, the agency has long been vulnerable to charges of conflicts of interest.

More:
California stem cell agency to review dealings with StemCells Inc.

Conflicts of interest at stem-cell agency yet again

Here we go again. In the decade since California voters established a one-of-a-kind state stem-cell research agency with $3 billion in bond funding, the agency has been in the news over and over because of conflicts of interests.

Members of the board governing the California Institute for Regenerative Medicine often are employed by institutions seeking board grants. While these members cant vote directly to give grants to their employers, the incentive for mutually beneficial voting is obvious. Thats why ethical complaints began almost as soon as the first grants were made.

Last year, finally, the institute added some strong new safeguards. Its key members then made the rounds at California newspapers to argue that it was time for the medias focus to shift to all the promising work that agency grants had yielded. Their argument seemed reasonable.

But this week, the U-T reported that recently resigned institute President Alan Trounson is joining the board of StemCells Inc. which got $19.4 million in grants from the agency.

Trounson hasnt broken any law, and agency officials are properly critical of his decision. But this still makes the stem-cell institute look shabby and the timing could hardly be worse. The original $3 billion in funding will be used up within three years.

Whether the institute seeks additional money from voters or the Legislature, its unsavory history will be hard to overcome.

Read more from the original source:
Conflicts of interest at stem-cell agency yet again

Patient-specific stem cells and personalized gene therapy

PUBLIC RELEASE DATE:

10-Jul-2014

Contact: Lucky Tran lt2549@cumc.columbia.edu 212-305-3689 Columbia University Medical Center

NEW YORK, NY (July 10, 2014) Columbia University Medical Center (CUMC) researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa (RP), a leading cause of vision loss. The approach, the first of its kind, takes advantage of induced pluripotent stem (iPS) cell technology to transform skin cells into retinal cells, which are then used as a patient-specific model for disease study and preclinical testing.

Using this approach, researchers led by Stephen H. Tsang, MD, PhD, showed that a form of RP caused by mutations to the gene MFRP (membrane frizzled-related protein) disrupts the protein that gives retinal cells their structural integrity. They also showed that the effects of these mutations can be reversed with gene therapy. The approach could potentially be used to create personalized therapies for other forms of RP, as well as other genetic diseases. The paper was published recently in the online edition of Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy.

"The use of patient-specific cell lines for testing the efficacy of gene therapy to precisely correct a patient's genetic deficiency provides yet another tool for advancing the field of personalized medicine," said Dr. Tsang, the Laszlo Z. Bito Associate Professor of Ophthalmology and associate professor of pathology and cell biology.

While RP can begin during infancy, the first symptoms typically emerge in early adulthood, starting with night blindness. As the disease progresses, affected individuals lose peripheral vision. In later stages, RP destroys photoreceptors in the macula, which is responsible for fine central vision. RP is estimated to affect at least 75,000 people in the United States and 1.5 million worldwide.

More than 60 different genes have been linked to RP, making it difficult to develop models to study the disease. Animal models, though useful, have significant limitations because of interspecies differences. Researchers also use human retinal cells from eye banks to study RP. As these cells reflect the end stage of the disease process, however, they reveal little about how the disease develops. There are no human tissue culture models of RP, as it would dangerous to harvest retinal cells from patients. Finally, human embryonic stem cells could be useful in RP research, but they are fraught with ethical, legal, and technical issues.

The use of iPS technology offers a way around these limitations and concerns. Researchers can induce the patient's own skin cells to revert to a more basic, embryonic stem celllike state. Such cells are "pluripotent," meaning that they can be transformed into specialized cells of various types.

In the current study, the CUMC team used iPS technology to transform skin cells taken from two RP patientseach with a different MFRP mutationinto retinal cells, creating patient-specific models for studying the disease and testing potential therapies.

Go here to see the original:
Patient-specific stem cells and personalized gene therapy

Stem cell researcher targets 'seeds' of breast cancer metastasis

For breast cancer patients, the era of personalized medicine may be just around the corner, thanks to recent advances by USC Stem Cell researcher Min Yu and scientists at Massachusetts General Hospital and Harvard Medical School.

In a July 11 study in Science, Yu and her colleagues report how they isolated breast cancer cells circulating through the blood streams of six patients. Some of these deadly cancer cells are the "seeds" of metastasis, which travel to and establish secondary tumors in vital organs such as the bone, lungs, liver and brain.

Yu and her colleagues managed to expand this small number of cancer cells in the laboratory over a period of more than six months, enabling the identification of new mutations and the evaluation of drug susceptibility.

If perfected, this technique could eventually allow doctors to do the same: use cancer cells isolated from patients' blood to monitor the progression of their diseases, pre-test drugs and personalize treatment plans accordingly.

In the six estrogen receptor-positive breast cancer patients in the study, the scientists found newly acquired mutations in the estrogen receptor gene (ESR1), PIK3CA gene and fibroblast growth factor receptor gene (FGFR2), among others. They then tested either alone or in combination several anticancer drugs that might target tumor cells with these mutations and identified which ones merit further study. In particular, the drug Ganetspib -- also known as STA-9090 -- appeared to be effective in killing tumor cells with the ESR1 mutation.

"Metastasis is the leading cause of cancer-related death," said Yu, assistant professor in the Department of Stem Cell Biology and Regenerative Medicine at the Keck School of Medicine of USC. "By understanding the unique biology of each individual patient's cancer, we can develop targeted drug therapies to slow or even stop their diseases in their tracks."

Story Source:

The above story is based on materials provided by University of Southern California - Health Sciences. The original article was written by Cristy Lytal. Note: Materials may be edited for content and length.

Visit link:
Stem cell researcher targets 'seeds' of breast cancer metastasis

Is there Scientific Evidence of How Stem Cell Therapy work in Autism Spectrum Disorder? – Video


Is there Scientific Evidence of How Stem Cell Therapy work in Autism Spectrum Disorder?
Dr. Hemangi Sane from Neurogen Brain and Spine Institute show Scientific Evidence of How Stem Cell Therapy work in Autism Spectrum Disorder. Published Paper ...

By: Neurogen Brain and Spine Institute

Go here to read the rest:
Is there Scientific Evidence of How Stem Cell Therapy work in Autism Spectrum Disorder? - Video

Stem Cells May Ease Urinary Incontinence, Study Says

By Maureen Salamon HealthDay Reporter Latest Womens Health News

FRIDAY, July 11, 2014 (HealthDay News) -- For the millions of women who can't cough, sneeze or laugh without losing bladder control, researchers are testing a treatment that uses stem cells to regenerate weakened urethra muscles.

In a small pilot study, European researchers found that injecting stem cells isolated from patients' own fat tissue improved or eliminated stress incontinence in all participants within a year.

Stress incontinence affects about twice as many women as men because of pelvic floor strain from pregnancy and childbirth.

Most women who choose to treat the condition undergo a procedure that inserts surgical mesh between the urethra and vagina to reduce urine leakage, urologists said. But widening controversy over the use of surgical mesh makes the idea of stem cell treatment even more attractive.

"This is an application that makes sense because of the ease of access to the urethra, which isn't a difficult area to inject," said Dr. Timothy Boone, chairman of urology at Houston Methodist Hospital in Texas, who wasn't involved in the study.

Globally, similar research is under way on the use of stem cells to treat stress incontinence.

However, "a lot of other stem cell therapies are a lot more invasive," Boone added. "It's too soon to tell, but the hope would be that a significant number of women would benefit from this and avoid the possible complications of surgery."

The study is published online in the July issue of the journal Stem Cells Translational Medicine.

Stress incontinence occurs when pelvic floor muscles supporting the bladder and urethra become too weak to prevent urine flow when pressure is placed on the abdomen. The problem can range from being a nuisance to highly debilitating.

See the original post:
Stem Cells May Ease Urinary Incontinence, Study Says

Injured Argentine winger Angel Di Maria may be resorting to unproven stem cell therapy

Im not betting on it, but if, by some miracle, Argentine winger Angel Di Maria is on the pitch against Germany Sunday in the 2014 World Cup final, get ready for another explosion of interest in stem cell therapy, a now familiar occurrence every time a famous athlete undergoes the treatment.

Di Maria, who either tore or strained a thigh muscle in Argentinas World Cup win over Belgium, is so determined to play in the final that, according to some reports, he is having the muscle injected with stem cells in the hope of healing by Sunday. (This Associated Press report from Thursday said he was practicing at 60 to 80 percent, so Im guessing were talking about a strain.)

If those reports are true, Di Maria will join a long line of elite athletes who have resorted to the unproven and possibly risky therapy. This kind of stem cell therapy is experimental in every sense of the word, according to the International Society for Stem Cell Research. There also is some evidence that the procedure can promote tumor growth or create an immune response to a patients own cells, or that injected stem cells might migrate to another part of the body.

Never mind. There is soccer to be played!

No one denies that stem cells hold promise as a therapy down the road, perhaps in as little as five or 10 years, says Kevin McCormack, communication director for the California Institute for Regenerative Medicine. With $3 billion supplied by voters in a 2004 ballot initiative, the organization is funding trials of the use of stem cell therapies for scarring after heart attacks, sickle cell anemia, leukemia and other conditions.

But for now, stem cells are known to be effective only for certain disorders of the blood, immune system and bone marrow. Beyond that, little has been proven, although clinics in the United States and around the world are offering the therapy and raking in bucks from desperate patients.

Di Maria may even see some benefits, McCormack said. In theory, they might [help] because they may have an anti-inflammatory effect or they may stimulate the bodys own natural healing, he said. But the problem is that they havent done any research to prove that.

The stem cells are harvested from a patients bone marrow and sometimes run through a centrifuge to concentrate them. Then they are injected into the damaged tissue.

For athletes, who are always looking for ways to prolong their careers and bounce back from injury, the fad began in 2010, when Major League pitcher Bartolo Colon had a slurry of stem cells that can turn into a variety of tissues injected into his injured elbow and shoulder. Within months, he was throwing 93 mile per hour fastballs for the New York Yankees. Later, Denver Broncos quarterback Peyton Manning, one of the most famous athletes in the United States, reportedly had stem cell therapy on his injured neck.

McCormack and others express concern that when pro athletes and other celebrities have unproven treatments, it sends the rest of us weekend warriors out in search of the same. Here a good bit of blame goes to us in the media. A 2012 analysis conducted for the journal Molecular Therapyshowed that 72.7 percen of the media coverage of athletes and stem cell therapy didnt address whether the treatment works, and 42 percent referred to alleged benefits. Only 5.7 percent of the stories brought up possible safety issues and risks.

Link:
Injured Argentine winger Angel Di Maria may be resorting to unproven stem cell therapy

No extra mutations in modified stem cells

The ability to switch out one gene for another in a line of living stem cells has only crossed from science fiction to reality within this decade. As with any new technology, it brings with it both promise-the hope of fixing disease-causing genes in humans, for example-as well as questions and safety concerns.

Now, Salk scientists have put one of those concerns to rest: using gene-editing techniques on stem cells doesn't increase the overall occurrence of mutations in the cells. The new results were published July 3 in the journal Cell Stem Cell.

"The ability to precisely modify the DNA of stem cells has greatly accelerated research on human diseases and cell therapy," says senior author Juan Carlos Izpisua Belmonte, professor in Salk's Gene Expression Laboratory. "To successfully translate this technology into the clinic, we first need to scrutinize the safety of these modified stem cells, such as their genome stability and mutational load."

When scientists want to change the sequence of a stretch of DNA inside cells-either for research purposes or to fix a genetic mutation for therapeutic purposes-they have their choice of two methods. They can use an engineered virus to deliver the new gene to a cell; the cell then integrates the new DNA sequence in place of the old one.

Or scientists can use what's known as custom targeted nucleases, such as TALEN proteins, which cut DNA at any desired location. Researchers can use the proteins to cut a gene they want to replace, then add a new gene to the mix. The cell's natural repair mechanisms will paste the new gene in place.

Previously, Belmonte's lab had pioneered the use of modified viruses, called helper-dependent adenoviral vectors (HDAdVs) to correct the gene mutation that causes sickle cell disease, one of the most severe blood diseases in the world.

He and his collaborators used HDAdVs to replace the mutated gene in a line of stem cells with a mutant-free version, creating stem cells that could theoretically be infused into patients' bone marrow so that their bodies create healthy blood cells.

Before such technologies are applied to humans, though, researchers like Belmonte wanted to know whether there were risks of editing the genes in stem cells. Even though both common gene-editing techniques have been shown to be accurate at altering the right stretch of DNA, scientists worried that the process could make the cells more unstable and prone to mutations in unrelated genes-such as those that could cause cancer.

"As cells are being reprogrammed into stem cells, they tend to accumulate many mutations," says Mo Li, a postdoctoral fellow in Belmonte's lab and an author of the new paper. "So people naturally worry that any process you perform with these cells in vitro-including gene editing-might generate even more mutations."

To find out whether this was the case, Belmonte's group, in collaboration with BGI and the Institute of Biophysics, Chinese Academy of Sciences in China, turned to a line of stem cells containing the mutated gene that causes sickle cell disease.

Here is the original post:
No extra mutations in modified stem cells